DILATED CARDIOMYOPATHY (DCM) Market Size & Share



DelveInsight’s ‘Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast —2030’ report delivers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Dilated Cardiomyopathy

 
Dilated Cardiomyopathy Overview

Cardiomyopathy is a general term that refers to the disorders of the cardiac muscle that cause mechanical or electrical dysfunction resulting in dilated, hypertrophic or restrictive pathophysiology. In Cardiomyopathy, the walls of the heart chambers become stretched, thickened or stiff; this affects the heart's ability to pump blood around the body. 
Dilated Cardiomyopathy (DCM) is characterized by left ventricular or biventricular dilation and impaired contraction, which lessens the heart effectiveness at pumping blood that is not explained by abnormal loading conditions like hypertension, valvular heart disease or coronary artery disease. It is a nonischemic heart muscle disease with structural and functional myocardial abnormalities.

Dilated Cardiomyopathy Diagnosis

The diagnosis of DCM is mainly based on the person's symptoms, the results of a physical examination, and additional tests. Diagnosis usually includes blood test for common viruses which can cause DCM and when doctors suspect infection as an underlying cause. Additionally, electrocardiography (ECG) may detect abnormalities in the electrical activity of the heart. 

Dilated Cardiomyopathy Treatment

 

Currently, the treatment pattern of DCM is mainly dependent on pharmacological therapy, pacing therapy, surgical options, and Corlanor (ivabradine). The pharmacological therapies consist of diuretics, inotropic agents, afterload reducing agents, beta-blockers, anticoagulation medications, anti-arrhythmia medications. The main diuretics that are prescribed for the treatment are furosemide, spironolactone, bumetanide, and metolazone. 

Request for sample report for Dilated Cardiomyopathy: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights



Dilated Cardiomyopathy Epidemiology Insights


• The total prevalent cases of Dilated Cardiomyopathy in the 7MM were found to be 2,486,633 in 2017 which is expected to grow during the study period, i.e., 2017–2030.
• As per the DelveInsight analysis, the total diagnosed cases of Dilated Cardiomyopathy in the 7MM were 846,615 cases in 2017 which is expected to grow during the study period, i.e., 2017–2030.
• As per the DelveInsight analysis, the total prevalent cases of Dilated Cardiomyopathy in the United States were 1,006,256 cases in 2017 which is expected to grow during the study period, i.e., 2017–2030.

Dilated Cardiomyopathy Approved Drug

 

Corlanor (ivabradine): Amgen

Dilated Cardiomyopathy Emerging Drugs

 

PF-07265803/ARRY-371797/ARRY-797: Pfizer

Ixmyelocel-T: Vericel

BC007: Berlin Cures GmbH

Dilated Cardiomyopathy Market Outlook

 

According to DelveInsight, Dilated Cardiomyopathy market in the 7MM is expected to change in the study period 2017–2030. The total therapeutic market of Dilated Cardiomyopathy in seven major markets was found to be USD 244 million in 2017 which is expected to increase during the study period (2017–2030).

Click here and download the full report on Dilated Cardiomyopathy.

 

Download sample pages: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights



Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more